Abnormalities in Clotting and Thrombolysis as a Risk Factor for Stroke

L. O Pilgeram

doi:10.1055/s-0038-1649159

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1974; 31(02): 245-264
DOI: 10.1055/s-0038-1649159

Original Article

Schattauer GmbH

Abnormalities in Clotting and Thrombolysis as a Risk Factor for Stroke

L. O Pilgeram

¹Coagulation Laboratory, Departments of Neurology and Physiology, Baylor College of Medicine, and the Baylor-Methodist Center for Cerebrovascular Research, Houston, Texas

› Author Affiliations

Abstract

Summary

Four hundred and six patients with ischemic thrombotic cerebrovascular disease (ITCVD) and 115 age-matched controls were studied to select risk factors which would identify ITCVD-prone individuals from a healthy population. The following factors were evaluated : soluble fibrin, plasminogen, plasminogen activator, fibrinogen, partial thromboplastin time, generation of thromboplastin, fibrin degradation products, triglycerides, type IV lipoproteinemia, and cholesterol. Discriminate function analyses were used to select those risk factors which best separate and classify the ITCVD and control subjects. The primary risk factors are the activated partial thromboplastin time, soluble fibrin, fibrinogen, and plasminogen activator. Utilizing only these four primary risk factors in a discriminate function, 93.2% of the patients were correctly classified. Consideration of other variables increased still further the dis-criminate function.

Full Text

References

References
1 Aggeler P. M, Kosmin M. Anticoagulation prophylaxis and treatment of venous thromboembolic disease. Thrombosis—National Academy of Sciences. 1969: 639
2 Alkjaersig N, Fletcher A. P, Sherry S. E-Aminocaproic acid: an inhibitor of plasminogen activation. Journal of Biological Chemistry 1959; 234: 832
3 Chaeytan C, Purtilo D. Glomerular capillary thrombosis and acute renal failure after E-Aminocaproic acid therapy. New England Journal of Medicine 1969; 280: 1102
4 Douglas A. S. 1969; Anticoagulant therapy in coronary artery disease. Thrombosis-National Academy of Sciences 690
5 Fearnley G. R. Measurement of spontaneous fibrinolytic activity. Journal of Clinical Pathology 1964; 17: 307
6 Fearnley G. R. 1970; Fibrinolysis and its pharmacological enhancement in occlusive vascular disease. Advances in Cardiology 4: 211
7 Gibinski K. Atherosclerose et coagulation. Revue Francaise d’études Cliniques et Biologiques 1966; 11: 185
8 Hampton J. W, Mantooth J, Brandt E. N, Wolf Jr S. G. 1966; Plasma fibrinogen patterns in patients with coronary atherosclerosis. Circulation 34: 1098
9 Hensen A, Kroes F, van Dyke L, Fekkes N, Hemker H, Loeliger E. A. A double blind study of phenprocoumon prophylaxis after a myocardial infarction. Thrombosis et Diathesis Haemorrhagica 1966; suppl 21: 333
10 Kessler G, Lederer H. Fluorometic measurements of triglycerides. Analytical Chemistry. Technicon Symposium. M. I., N. Y. 1965
11 Kipshidze N. N, Tordiya M. B, Dzhavakhishvili N. N. Changes in the blood system in longevity. Federation Proceedings (Abstract) 1964; 23: 1247
12 Kisker C. D, Rush R. Detection of intravascular coagulation. Journal of Clinical Investigation 1971; 50: 2235
13 Loewy A. G, Dunathan K, Kriel R, Woleinger Jr H. L. 1961; Fibrinase: Purification of substrate and enzyme. Journal of Biological Chemistry 236: 2625
14 Merskey C. G, Kleiner J, Johnson A.J. Quantitative estimation of split products of fibrinogen in human serum: relation to diagnosis and treatment. Blood 28: 1
15 Merskey C, Johnson A. J. 1966; Diagnosis and treatment of intravascular coagulation. Thrombosis et Diathesis Haemorrhagica 1966; supp 21: 555
16 Mertens B. F, McDuffie F. C, Bowie J. W, Owen Jr. C. A. Rapid sensitive method for measuring fibrinogen split products in human serum. Mayo Clinic Proceedings 1969; 44: 114
17 Murphy E. A, Mustard J. F. 1962; Coagulation test and platelet economy in atherosclerotic and control subjects. Circulation 25: 114
18 Niewiarowski S, Wolosowicz N. The In-Vivo effect of E-Aminocaproic acid on the human plasma fibrinolytic system. Thrombosis et Diathesis Haemorrhagica 1966; 15: 491
19 Owen Jr. C. A, Didisheim P, Thompson Jr. J. H, Spittel Jr. J.A. Factor VIII and TGA types of hypercoagulability. Thrombosis -National Academy of Sciences. 1969: 573
20 Pascuzzi C. A, Spittel Jr. J, Thompson Jr. J. H, Owen Jr. C. A. Thromboplastin generation accelerator. a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. Journal of Clinical Investigation 1961; 40: 1006
21 Penick G. D. Blood states that predispose to thrombosis. Thrombosis-National Academy of Sciences. 1969: 553
22 Penick G. D, Dejanov I. I, Roberts H. R, Webster W. P. Elevation of factor VIII in hypercoagulable states. In Koller F. (Ed.) Diffuse Intravascular Clotting: F. K. Schattauer (Stuttg.); 1965: 39
23 Pilgeram L. O. 1961; The relation of plasma fibrinogen concentration changes to human atherosclerosis. Journal of Applied Physiology 16: 660
24 Pilgeram L. O. Turnover rate of autologous plasma fibrinogen ¹⁴C in subjects with coronary thrombosis. Thrombosis et Diathesis Haemorrhagica 1968; 20: 31
25 Pilgeram L. O, Amundson B, Lofgren P. E. Evidence for steroid control of the metabolism of Profibrinolysin. Thrombosis et Diathesis Haemorrhagica 1964; 11: 94
26 Pilgeram L. O, Commers L. R. Oxalate induced correction of the plasma antithromboplastin deficiency in the aging arteriosclerotic subject. Thrombosis et Diathesis Haemorrhagica 1964; 10: 350
27 Pilgeram L. O, Pickart L. R. Control of fibrinogen biosynthesis: The role of the free fatty acid. Journal of Atherosclerosis Research 1968; 8: 155-166.
28 Pilgeram L. O, SchrAm A. C. Correlation of activity changes in blood coagulation factors with human arteriosclerosis. Circulation (Abstract) 1959; 20: 991
29 Pilgeram L. O, SchrAm A. C, Loegering D. A. Elevation of plasma antithrombin in the aging arteriosclerotic subject. Journal of Applied Physiology 1963; 18: 329
30 Pilgeram L. O, SchrAm A. C, Mills D. Specificity of plasma fibrinogen changes in arterosclerosis. Circulation (Abstract) 1960; 22: 668
31 Procedure N 24a. Auto Analyzer Manual. Chauncey. New York: Technicon Instruments.; 1964
32 Proctor R. R, Rapaport S. I. The partial thromboplastin time with Kaolin. American Journal of Clinical Pathology 1961; 36: 212
33 Remue W. Thromboseprophylaxe bei kardialer Dekompensation. Medizinische Monatsschrift 1961; 15: 380
34 Schmid H. J, Jackson D. P, Conley C. L. Mechanism of action of thrombin on platelets. Journal of Clinical Investigation 1961; 41: 543
35 Spittel J. A, Pacuzzi C. A, Thompson J. H, Owen Jr. C. A. Acceleration of early stages of coagulation in certain patients with occlusive arterial or venous diseases : Use of a modified thromboplastin generation test to evaluate clot acceleration. Proceedings of the Mayo Clinic 1960; 35: 37
36 Steinmann B. Über Beziehungen zwischen Cholesterin- und Fibrinogen-Gehalt. Thromboembolien und Atherosklerose. Gerontología 1965; 10: 100
37 World Health Organization 1970; 43: 891
38 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products in renal venous blood in dog. Thrombosis et Diathesis Haemorrhagica 1964; 12: 87